

Literatur

1. Morton JJ, Connell JM, Hughes MJ, Inglis GC, Wallace EC. The role of plasma osmolality, angiotensin II and dopamine in vasopressin release in man. *Clin Endocrinol Oxf* 1985; 23:129-38.
2. Medvei VC. *A History of Endocrinology*. Boston, 1982:830.
3. Reeves WB, Andreoli TE. The posterior pituitary and water metabolism. *Williams Textbook of Endocrinology*. Philadelphia: Wilson, J. D., Foster, D. W., 1992:311-356.
4. Bettendorf G. *Zur Geschichte der Endokrinologie und Reproduktionsmedizin*. Berlin, 1995.
5. Gruber H. Innerer Aufbau und Leitungsbahnen des Zwischenhirns. In: Fleischhauer K, ed. *Benninghoff Anatomie Makroskopische und mikroskopische Anatomie des Menschen 3 Nervensystem, Haut und Sinnesorgane*. München, Wien, Baltimore, 1985:321-351.
6. McKenna K, Thompson C. Osmoregulation in clinical disorders of thirst appreciation. *Clin Endocrinol* 1998; 49:139-52.
7. Cross B, Dyball R, Dyer R, et al. Endocrine neurons. *Recent Prog Horm Res* 1975; 31:243-94.
8. Thrasher TN, Keil LC, Ramsay DJ. Lesions of the organum vasculosum of the lamina terminalis (OVLT) attenuate osmotically-induced drinking and vasopressin secretion in the dog. *Endocrinology* 1982; 110:1837-9.
9. Zimmerman EA, Ma LY, Nilaver G. Anatomical basis of thirst and vasopressin secretion. *Kidney Int Suppl* 1987; 21:S14-9.
10. Brownstein MJ, Russell JT, Gainer H. Synthesis, transport, and release of posterior pituitary hormones. *Science* 1980; 207:373-8.
11. Kritz W. Die Nieren. In: Fleischhauer K, ed. *Benninghoff Anatomie Makroskopische und mikroskopische Anatomie des Menschen 2 Kreislauf und Eingeweide*. München, Wien, Baltimore, 1985:413-450.
12. Whitnall MH, Mezey E, Gainer H. Co-localization of corticotropin-releasing factor and vasopressin in median eminence neurosecretory vesicles. *Nature* 1985; 317:248-50.
13. Asplund R. The nocturnal polyuria syndrome (NPS). *Gen Pharmacol* 1995; 26:1203-9.
14. Moses AM, Streeten DH. Disorders of the Neurohypophysis. *Harrison's Principles of Internal Medicine*. Vol. 2. New York: Isselbacher, K. J., Braunwald, E., Wilson, J. D., Martin, J. B., Fauci, A. S., Kasper, D. L., 1994:1921-1929.
15. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. *J Clin Invest* 1976; 57:1109-16.
16. Claybaugh JR, Sato AK. Factors influencing urinary vasopressin concentration. *Fed Proc* 1985; 44:62-5.
17. Nitschke U, Balzar H. Inactivation of infused vasopressin in diabetes insipidus probands. *Acta Endocrinol Copenh* 1969; 62:270-82.
18. Pruszczyński W, Caillens H, Drieu L, Moulonguet Doleris L, Ardaillou R. Renal excretion of antidiuretic hormone in healthy subjects and patients with renal failure. *Clin Sci* 1984; 67:307-12.

19. Miller M, Moses AM. Radioimmunoassay of urinary antidiuretic hormone in man: response to water load and dehydration in normal subjects. *J Clin Endocrinol Metab* 1972; 34:537-45.
20. Dunn F, Brennan T, Nelson A, Robertson G. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. *J Clin Invest* 1973; 52:3212-9.
21. Robertson GL, Mahr E, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. *J Clin Invest* 1973; 52:2340-52.
22. Sved AS. Central Neural Pathways in Baroreceptor Control of Vasopressin Secretion. In: Schrier RW, ed. *Vasopressin*. New York, 1985:443-453.
23. Zimmerman MB, Blaine EH, Stricker EM. Water intake in hypovolemic sheep: effects of crushing the left atrial appendage. *Science* 1981; 211:489-91.
24. Brooks DP, Share L, Crofton JT. Vasopressin: The Control of Its Release and Cardiovascular Actions. In: Schrier RW, ed. *Vasopressin*. New York, 1985:69-77.
25. Simon-Oppermann C, Günther O. ADH, renal, and circulatory responses to adrenergic stimulation in anterior third ventricle. *Am J Physiol* 1990; 259:R294-304.
26. Phillips PA, Rolls BJ, Ledingham JG, Morton JJ, Forsling ML. Angiotensin II-induced thirst and vasopressin release in man. *Clin Sci* 1985; 68:669-74.
27. Dillingham MA, Anderson JA. Inhibition of vasopressin action by atrial natriuretic factor. *Science* 1986; 231:1572-3.
28. Seckl JR, Williams-TD, Lightman-SL. Oral hypertonic saline causes transient fall of vasopressin in humans. *Am J Physiol* 1986; 251:R214-7.
29. Geelen G, Keil LC, Kravik SE, et al. Inhibition of plasma vasopressin after drinking in dehydrated humans. *Am J Physiol* 1984; 247:R968-71.
30. Rowe JW, Shelton RL, Helderman JH, Vestal RE, Robertson GL. Influence of the emetic reflex on vasopressin release in man. *Kidney Int* 1979; 16:729-35.
31. Grossman A, Besser GM, Milles JJ, Baylis PH. Inhibition of vasopressin release in man by an opiate peptide. *Lancet* 1980; 2:1108-10.
32. Oiso Y, Robertson GL. Effect of Ethanol on Vasopressin Secretion and the Role of Endogenous Opioids. In: Schrier RW, ed. *Vasopressin*. New York, 1985:265-269.
33. Baylis PH, Heath DA. Plasma-arginine-vasopressin response to insulin-induced hypoglycaemia. *Lancet* 1977; 2:428-30.
34. Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. *N Engl J Med* 1989; 321:492-6.
35. Jenkins JS. Thirst and vasopressin [comment]. *Clin Endocrinol* 1991; 35:219-20.
36. Thompson CJ, Edwards CR, Baylis PH. Osmotic and non-osmotic regulation of thirst and vasopressin secretion in patients with compulsive water drinking. *Clin Endocrinol* 1991; 35:221-8.

37. Robertson GL. Abnormalities of thirst regulation. *Kidney Int* 1984; 25:460-9.
38. Phillips PA, Rolls BJ, Ledingham JG, Forsling ML, Morton JJ. Osmotic thirst and vasopressin release in humans: a double-blind crossover study. *Am J Physiol* 1985; 248:R645-50.
39. Thompson CJ, Bland J, Burd J, Baylis PH. The osmotic thresholds for thirst and vasopressin release are similar in healthy man. *Clin Sci* 1986; 71:651-6.
40. Verkman AS. Mechanisms and regulation of water permeability in renal epithelia. *Am J Physiol* 1989; 257:C837-50.
41. Baylis PH, Cheetham T. Diabetes insipidus. *Arch Dis Child* 1998; 79:84-9.
42. Molony DA, Reeves WB, Andreoli TE. Na⁺:K⁺:2Cl⁻ cotransport and the thick ascending limb. *Kidney Int* 1989; 36:418-26.
43. Dixey JJ, Williams TD, Lightman SL, Lant AF, Brewerton DA. The effect of indomethacin on the renal response to arginine vasopressin in man. *Clin Sci* 1986; 70:409-16.
44. Smith PM, Ferguson AV. Vasopressin acts in the subfornical organ to decrease blood pressure. *Neuroendocrinology* 1997; 66:130-5.
45. Hader O. Untersuchung über den Einfluß von exogenem und von osmotisch stimuliertem endogenem Vasopressin auf die ACTH-Sekretion beim Menschen. Berlin, 1988.
46. Robertson GL. Diabetes insipidus. *Endocrinol Metab Clin North Am* 1995; 24:549-72.
47. Robertson GL. Differential diagnosis of polyuria. *Annu Rev Med* 1988; 39:425-42.
48. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. *N Engl J Med* 1988; 318:397-403.
49. Hensen J, Dolz M, Oelkers W. Transient polyuria in pregnancy in diabetes insipidus and gestational diabetes. *Med Klin* 1991; 86:623-8.
50. Zerbe R, Robertson G. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. *N Engl J Med* 1981; 305:1539-46.
51. Arnaout MA, Ajlouni K. Plasma vasopressin responses in postpartum hypopituitarism: impaired response to osmotic stimuli. *Acta Endocrinol Copenh* 1992; 127:494-8.
52. Poon WS, Lolin YI, Yeung TF, et al. Water and sodium disorders following surgical excision of pituitary region tumours. *Acta Neurochir Wien* 1996; 138:921-7.
53. Seckl JR, Dunger DB, Lightman SL. Neurohypophyseal peptide function during early postoperative diabetes insipidus. *Brain* 1987; 110:737-46.
54. McIver B, Connacher A, Whittle I, Baylis P, Thompson C. Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm. *BMJ* 1991; 303:1465-7.
55. Fischer B, Muller Quernheim J, Ferlinz R. Diabetes insipidus in sarcoidosis. *Pneumologie* 1991; 45:100-4.
56. Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. *N Engl J Med* 1989; 321:1157-62.

57. Madhoun ZT, DuBois DB, Rosenthal J, Findlay JC, Aron DC. Central diabetes insipidus: a complication of herpes simplex type 2 encephalitis in a patient with AIDS. *Am J Med* 1991; 90:658-9.
58. Van Maldergem L, Gillerot Y, Vamos E, Toppet M, Watillon P, Van Vliet G. Vasopressin and gonadotropin deficiency in a boy with the ectrodactyly-ectodermal dysplasia-clefting syndrome. *Acta Paediatr* 1992; 81:365-7.
59. Cemeroglu AP, Blaivas M, Muraszko KM, Robertson PL, Vazquez DM. Lymphocytic hypophysitis presenting with diabetes insipidus in a 14-year-old girl: case report and review of the literature. *Eur J Pediatr* 1997; 156:684-8.
60. Imura H, Nakao K, Shimatsu A, et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. *N Engl J Med* 1993; 329:683-9.
61. McLeod JF, Kovacs L, Gaskill MB, Rittig S, Bradley GS, Robertson GL. Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation [see comments]. *J Clin Endocrinol Metab* 1993; 77:599A-599G.
62. Pedersen EB, Lamm LU, Albertsen K, et al. Familial cranial diabetes insipidus: a report of five families. Genetic, diagnostic and therapeutic aspects. *Q J Med* 1985; 57:883-96.
63. Barrett TG, Bunday SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. *Lancet* 1995; 346:1458-63.
64. Thompson CJ, Charlton J, Walford S, et al. Vasopressin secretion in the DIDMOAD (Wolfram) syndrome. *Q J Med* 1989; 71:333-45.
65. Vokes TJ, Gaskill MB, Robertson GL. Antibodies to vasopressin in patients with diabetes insipidus. Implications for diagnosis and therapy. *Ann Intern Med* 1988; 108:190-5.
66. De Bellis A, Bizzarro A, Amoresano Paglionico V, et al. Detection of vasopressin cell antibodies in some patients with autoimmune endocrine diseases without overt diabetes insipidus. *Clin Endocrinol Oxf* 1994; 40:173-7.
67. Baylis PH. Understanding the cause of idiopathic cranial diabetes insipidus: a step forward. *Clin Endocrinol Oxf* 1994; 40:171-2.
68. Weiss NM, Robertson GL. Effect of Hypercalcemia and Lithium Therapy on the Osmoregulation of Thirst and Vasopressin Secretion. In: Schrier RW, ed. *Vasopressin*. New York, 1985:281-289.
69. Goldman MB, Robertson GL, Luchins DJ, Hedeker D, Pandey GN. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. *Arch Gen Psychiatry* 1997; 54:443-9.
70. Iwasaki Y, Oiso Y, Kondo K, et al. Aggravation of subclinical diabetes insipidus during pregnancy. *N Engl J Med* 1991; 324:522-6.
71. Moses AM, Clayton B. Impairment of osmotically stimulated AVP release in patients with primary polydipsia. *Am J Physiol* 1993; 265:R1247-52.
72. Thompson CJ, Baylis PH. Thirst in diabetes insipidus: clinical relevance of quantitative assessment. *Q J Med* 1987; 65:853-62.
73. Baylis PH, Gaskill MB, Robertson GL. Vasopressin secretion in primary polydipsia and cranial diabetes insipidus. *Q J Med* 1981; 50:345-58.

74. Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. *Ann Intern Med* 1970; 73:721-9.
75. Hensen J, Hader O, Bahr V, Oelkers W. Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. *J Clin Endocrinol Metab* 1988; 66:668-71.
76. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine⁸-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. *Clin Chem* 1999; 45:98-103.
77. Miller M, Moses AM. Urinary antidiuretic hormone in polyuric disorders and in inappropriate ADH syndrome. *Ann Intern Med* 1972; 77:715-21.
78. Oyama SN, Kagan A, Glick SM. Radioimmunoassay of vasopressin: application to unextracted human urine. *J Clin Endocrinol Metab* 1971; 33:739-44.
79. Padilla G, Leake JA, Castro R, Ervin MG, Ross MG, Leake RD. Vasopressin levels and pediatric head trauma. *Pediatrics* 1989; 83:700-5.
80. Padilla G, Ervin MG, Ross MG, Leake RD. Vasopressin levels in infants during the course of aseptic and bacterial meningitis. *Am J Dis Child* 1991; 145:991-3.
81. Puri VN. Urinary anti diuretic hormone level in essential hypertension. *Pharmacol Res Commun* 1987; 19:53-8.
82. Dunger DB, Seckl JR, Grant DB, Yeoman L, Lightman SL. A short water deprivation test incorporating urinary arginine vasopressin estimations for the investigation of posterior pituitary function in children. *Acta Endocrinol Copenh* 1988; 117:13-8.
83. Moses AM. Osmotic thresholds for AVP release with the use of plasma and urine AVP and free water clearance. *Am J Physiol* 1989; 256:R892-7.
84. Forth W, Henschler D, Rummel W. Allgemeine und spezielle Pharmakologie und Toxikologie. Mannheim, Wien, Zürich, 1990:407-409.
85. Chanson P, Jedynak CP, Czernichow P. Management of early postoperative diabetes insipidus with parenteral desmopressin. *Acta Endocrinol Copenh* 1988; 117:513-6.
86. Chanson P, Jedynak CP, Dabrowski G, et al. Ultralow doses of vasopressin in the management of diabetes insipidus. *Crit Care Med* 1987; 15:44-6.
87. Fjellestad Paulsen A, Tubiana Ruffi N, Harris A, Czernichow P. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. *Acta Endocrinol Copenh* 1987; 115:307-12.
88. Fjellestad A, Czernichow P. Central diabetes insipidus in children. V. Oral treatment with a vasopressin hormone analogue (DDAVP). *Acta Paediatr Scand* 1986; 75:605-10.
89. Ziegler R, Pickard C, Willig R. Rationelle Diagnostik in der Endokrinologie. Stuttgart, New York, 1993.
90. Skowsky WR, Fisher DA. The use of thyroglobulin to induce antigenicity to small molecules. *J Lab Clin Med* 1972; 80:134-44.

91. Bichet DG, Arthus MF, Barjon JN, Lonergan M, Kortas C. Human platelet fraction arginine-vasopressin. Potential physiological role. *J Clin Invest* 1987; 79:881-7.
92. Rodbard D. Statistical estimation of the minimal detectable concentration for radioligand assays. *Anal Biochem* 1978; 90:1-12.
93. Vasopressin Radioimmunoassay Kit (Vorläufige Arbeitsanleitung). Wjchen: Nichols Institute Diagnostics BV, 1992.
94. Gardner MJ, Altman DG. *Statistics with Confidence*. London: British Medical Journal, 1989.
95. Tausch A, Stegner H, Leake RD, Artman HG, Fisher DA. Radioimmunoassay of arginine vasopressin in urine: development and application. *J Clin Endocrinol Metab* 1983; 57:777-81.
96. Moses AM, Steciak E. Urinary and metabolic clearances of arginine vasopressin in normal subjects. *Am J Physiol* 1986; 251:R365-70.
97. Panzali A, Signorini C, Ferrari R, Albertini A. Direct determination of arginine-vasopressin in urine. *Clin Chem* 1990; 36:384-5.
98. Khokhar AM, Ramage CM, Slater JD. Radioimmunoassay of arginine-vasopressin in human urine and its use in physiological and pathological states. *J Endocrinol* 1978; 79:375-89.
99. Fletcher RH, Fletcher SW, Wagner EH. *Klinische Epidemiologie Grundlagen und Anwendung*. In: Haerting J, Rink C, eds: Ullstein Medical, 1999.